As filed with the Securities and Exchange Commission on March 12, 2021
Registration No. 333-
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM S-8
REGISTRATION STATEMENT
UNDER
THE SECURITIES ACT OF 1933
PROMETHEUS BIOSCIENCES, INC.
(Exact name of registrant as specified in its charter)
| | | | |
Delaware | | | | 81-4282653 |
(State or Other Jurisdiction of Incorporation or Organization) | | | | (I.R.S. Employer Identification No.) |
9410 Carroll Park Drive
San Diego, California 92121
(858) 824-0895
(Address of Principal Executive Offices)
PROMETHEUS BIOSCIENCES, INC. 2017 EQUITY INCENTIVE PLAN
PROMETHEUS BIOSCIENCES, INC. 2021 INCENTIVE AWARD PLAN
PROMETHEUS BIOSCIENCES, INC. 2021 EMPLOYEE STOCK PURCHASE PLAN
(Full Title of the Plans)
Mark C. McKenna
President and Chief Executive Officer
Prometheus Biosciences, Inc.
9410 Carroll Park Drive
San Diego, California 92121
(858) 824-0895
(Name, Address and Telephone Number, Including Area Code, of Agent for Service)
Copies to:
Cheston J. Larson
Matthew T. Bush
Michael E. Sullivan
Latham & Watkins LLP
12670 High Bluff Drive
San Diego, California 92130
(858) 523-5400
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer or a smaller reporting company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act.
| | | | | | |
Large accelerated filer | | ☐ | | Accelerated filer | | ☐ |
| | | |
Non-accelerated filer | | ☒ | | Smaller reporting company | | ☒ |
| | | |
| | | | Emerging growth company | | ☒ |
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐
CALCULATION OF REGISTRATION FEE
| | | | | | | | |
|
Title of Each Class of Securities to be Registered | | Amount to be Registered (1) | | Proposed Maximum Offering Price Per Share | | Proposed Maximum Aggregate Offering Price | | Amount of Registration Fee |
Common stock, $0.0001 par value | | 7,547,000 shares (2) | | $19.00 (3) | | $143,393,000 | | $15,644.18 |
Common stock, $0.0001 par value | | 53,000 shares (4) | | $19.00 (5) | | $1,007,000 | | $109.86 |
Common stock, $0.0001 par value | | 4,978,932 shares (6) | | $4.43 (7) | | $22,056,669 | | $2,406.38 |
Common stock, $0.0001 par value | | 1,160,000 shares (8) | | $19.00 (3) | | $22,040,000 | | $2,404.56 |
Total | | 13,738,932 shares | | — | | $188,496,669 | | $20,564.98 |
|
|
(1) | Pursuant to Rule 416 under the Securities Act of 1933, as amended (the “Securities Act”), this registration statement also registers an indeterminate number of additional shares that may be issued pursuant to the above-named plans as the result of any future stock dividend, stock split, recapitalization or any other similar transaction effected without the receipt of consideration which results in an increase in the number of our outstanding shares of common stock. |
(2) | Represents 7,547,000 shares of common stock available for future issuance under the Prometheus Biosciences, Inc. 2021 Incentive Award Plan (the “2021 Plan”), which number consists of (a) 3,547,000 shares of common stock initially available for future grants under the 2021 Plan, and (b) up to an additional 4,000,000 shares of common stock that may become issuable under the 2021 Plan pursuant to its terms. To the extent outstanding awards under the 2021 Plan or the Prometheus Biosciences, Inc. 2017 Equity Incentive Plan (the “2017 Plan”) are forfeited or lapse unexercised, the shares of common stock subject to such awards will be available for future issuance under the 2021 Plan. See footnote 6 below. |
(3) | This estimate is made pursuant to Rule 457 of the Securities Act solely for purposes of calculating the registration fee. The computation is based upon the initial public offering price of the registrant’s common stock set forth on the cover page of the registrant’s prospectus dated March 12, 2021 relating to its initial public offering. |
(4) | Represents 53,000 shares of common stock subject to outstanding options under the 2021 Plan. To the extent outstanding options under the 2021 Plan are forfeited or lapse unexercised, the shares of common stock subject to such awards will be available for future issuance under the 2021 Plan. |
(5) | This estimate is made pursuant to Rule 457 of the Securities Act solely for purposes of calculating the registration fee. The Proposed Maximum Offering Price Per Share is $19.00 per share, which is the weighted average exercise price of outstanding options granted under the 2021 Plan being registered. |
(6) | Represents 4,978,932 shares of common stock subject to outstanding options under the 2017 Plan. To the extent outstanding options under the 2017 Plan are forfeited or lapse unexercised, the shares of common stock subject to such awards will be available for future issuance under the 2021 Plan. See footnote 2 above. |
(7) | This estimate is made pursuant to Rule 457 of the Securities Act solely for purposes of calculating the registration fee. The Proposed Maximum Offering Price Per Share is $4.43 per share, which is the weighted average exercise price of outstanding options granted under the 2017 Plan being registered. |
(8) | Represents 1,160,000 shares of common stock available for future issuance under the Prometheus Biosciences, Inc. 2021 Employee Stock Purchase Plan (the “ESPP”), which number consists of (a) 360,000 shares of common stock initially available for future grants under the ESPP, and (b) up to an additional 800,000 shares of common stock that may become issuable under the ESPP pursuant to its terms. |
Proposed sales to take place as soon after the effective date of the registration statement as awards granted under the above-named plans are granted, exercised and/or distributed.